EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Integrating and optimizing tonabersat in standard glioblastoma therapy: A preclinical study

Velislava Zoteva iD, Valerie De Meulenaere, Christian Vanhove iD, Luc Leybaert, Robrecht Raedt, Leen Pieters, Anne Vral, Tom Boterberg, Karel Deblaere

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0300552 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Velislava Zoteva und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Ghent University, Ghent, Belgium. Hauptthemen laut MEDLINE: Glioblastoma, Brain Neoplasms, Benzamides, Benzopyrans. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioblastoma (GB), a highly aggressive primary brain tumor, presents a poor prognosis despite the current standard therapy, including radiotherapy and temozolomide (TMZ) chemotherapy. Tumor microtubes involving connexin 43 (Cx43) contribute to glioma progression and therapy resistance, suggesting Cx43 inhibition as a potential treatment strategy. This research aims to explore the adjuvant potential of tonabersat, a Cx43 gap junction modulator and blood-brain barrier-penetrating compound, in combination with the standard of care for GB. In addition, different administration schedules and timings to optimize tonabersat’s therapeutic window are investigated. The F98 Fischer rat model will be utilized to investigate tonabersat’s impact in a clinically relevant setting, by incorporating fractionated radiotherapy (three fractions of 9 Gy) and TMZ chemotherapy (29 mg/kg). This study will evaluate tonabersat’s impact on tumor growth, survival, and treatment response through advanced imaging (CE T1-w MRI) and histological analysis. Results show extended survival in rats receiving tonabersat with standard care, highlighting its adjuvant potential. Daily tonabersat administration, both preceding and following radiotherapy, emerges as a promising approach for maximizing survival outcomes. The study suggests tonabersat’s potential to reduce tumor invasiveness, providing a new avenue for GB treatment. In conclusion, this preclinical investigation highlights tonabersat’s potential as an effective adjuvant treatment for GB, and its established safety profile from clinical trials in migraine treatment presents a promising foundation for further exploration.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaBrain NeoplasmsBenzamidesBenzopyransRatsAnimalsConnexin 43Standard of CareTemozolomideRats, Inbred F344Antineoplastic Agents, Alkylating

Substanzen

tonabersatConnexin 43TemozolomideAntineoplastic Agents, AlkylatingBenzamidesBenzopyrans

Autor:innen und Institutionen

  • Department of Radiology, Ghent University, Ghent, Belgium.
  • IBiTech-Medisip-Infinity lab, Ghent University, Ghent, Belgium.
  • Physiology Group, Department of Basic and Applied Medical Sciences, Ghent University, Ghent, Belgium.
  • Department of Head and Skin, Ghent University, Ghent, Belgium.
  • Department of Human Structure and Repair, Ghent University, Ghent, Belgium.
  • Department of Radiation Oncology, Ghent University Hospital, Ghent, Belgium.

ORCID-Profile: Velislava Zoteva, Christian Vanhove

Zitieren

APA

Zoteva, V., De Meulenaere, V., Vanhove, C., Leybaert, L., Raedt, R., Pieters, L., Vral, A., Boterberg, T., & Deblaere, K. (2024). Integrating and optimizing tonabersat in standard glioblastoma therapy: A preclinical study. PLOS ONE. https://doi.org/10.1371/journal.pone.0300552

Vancouver

Zoteva V, De Meulenaere V, Vanhove C, Leybaert L, Raedt R, Pieters L, et al. Integrating and optimizing tonabersat in standard glioblastoma therapy: A preclinical study. PLOS ONE. 2024. doi:10.1371/journal.pone.0300552

BibTeX
@article{Zoteva2024,
  author = {Zoteva, Velislava and De Meulenaere, Valerie and Vanhove, Christian and Leybaert, Luc and Raedt, Robrecht and Pieters, Leen and Vral, Anne and Boterberg, Tom and Deblaere, Karel},
  title = {Integrating and optimizing tonabersat in standard glioblastoma therapy: A preclinical study},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0300552}
}
Kostenlos starten →